Introduction
============

Gastric and colorectal cancers remain the major causes of cancer-related death and have bad prognosis to date.[@b1-ott-9-3683]--[@b3-ott-9-3683] Surgery has been the common choice for managing early-stage and advanced gastrointestinal malignancies. Unfortunately, many patients relapse with local recurrence or distant metastasis after surgery.[@b4-ott-9-3683] On the other hand, about 20%--30% patients were diagnosed as having inoperable disease initially. Hence, a systemic therapy is needed for the majority of patients at some point during the course of the disease. Palliative, neoadjuvant, and adjuvant chemotherapy have been widely used for gastrointestinal cancers.[@b5-ott-9-3683]

Up to now, 5-fluropyrimidines, oxaliplatin, irinotecan, and monoclonal antibodies such as cetuximab, panitumumab, and bevacizumab are the most common drugs for gastrointestinal cancers in chemotherapy.[@b6-ott-9-3683] Although chemotherapy improves prognosis of the patients with gastrointestinal cancers, some patients do not benefit from the therapy and are exposed to the adverse effects.[@b7-ott-9-3683],[@b8-ott-9-3683] One major cause of different efficacy resulting from a homologous regimen may be the individual genetic variation in genes associated with detoxification, metabolism, DNA repair, excretion, or transport.[@b9-ott-9-3683]

*GSTM1* and *GSTT1* are members of the glutathione *S*-transferase (GST) family and are involved in the detoxification pathway of a wide variety of electrophiles, including chemotherapeutic agents. A null polymorphism or total gene deletion of the two genes will block the gene activity.

In recent years, a series of studies have been conducted to investigate the associations of *GSTM1* and *GSTT1* polymorphisms with clinical outcomes of chemotherapy, including toxicities, tumor response, and progression-free survival/overall survival (PFS/OS) in gastric or colorectal cancer; however, the results were inconsistent and inconclusive. Here, a systematic review and meta-analysis was performed, for the first time, to explore these associations.

Materials and methods
=====================

Publication search
------------------

A systematic search was performed for published articles on the relationship between glutathione *S*-transferases M1 or T1 polymorphisms and chemotherapy in gastrointestinal cancers using the following search terms: "gastric or stomach or colorectal or colon or rectal," "cancer or tumor or carcinoma," "polymorphism or polymorphisms or variant" "glutathione S-transferase M1 or glutathione S-transferase T1 or *GSTM1* or *GSTT1*," and "chemotherapy" in English databases (PubMed, EMBASE, and Web of Science) with the last search update on January 10, 2016. Two independent authors screened and selected the retrieved articles according to the inclusion and exclusion criteria. The review articles and the references of selected articles were also screened to identify additional eligible studies.

Inclusion and exclusion criteria
--------------------------------

The inclusion criteria were as follows: 1) studies evaluating the relationship between glutathione *S*-transferases M1 or T1 polymorphisms and chemotherapy efficacy including toxicities, tumor response, and/or PFS/OS; 2) studies performed in gastric cancer or colorectal cancer; and 3) studies in which genotype frequency data was specific to clinical features and/or prognosis and could be obtained. Exclusion criteria were as follows: 1) studies including patients with carcinoma other than gastric or colorectal cancers; 2) studies with insufficient or duplicate data; and 3) studies that were not original research articles, such as abstracts, letters, or review articles.

Data extraction
---------------

Two independent authors collected data from all eligible studies in duplicate. A predefined table containing the following terms was used: name of first author, year of publication, country of origin, study type, cancer type, ethnicity cases number, sex, mean age, Eastern Cooperative Oncology Group (ECOG) score, Karnofsky scale, metastatic sites number, disease stage/grade, pre-/postsurgery data, prechemotherapy/-radiotherapy details, responder definition, genotyping method, chemotherapy strategy, chemotherapy type, toxicity type, evaluation criteria, and genotype data. Inconsistency was resolved by discussion.

Statistical analysis
--------------------

The crude odds ratios (ORs) and hazard ratios (HRs) and their 95% confidence intervals (95% CIs) were calculated to assess the strength of association between *GSTM1* or *GSTT1* polymorphism and chemotherapy outcomes in gastric and colorectal cancers. The statistical significant level was determined by *Z*-test, with *P*-value less than 0.05. The heterogeneity was assessed by the chi-square test based on *Q*-statistic test, with a *P*-value \<0.1 or *I*^2^\>50%. If *P*\>0.1and *I*^2^\<50%, the pooled OR and 95% CIs were calculated by the fixed effects model (Mantel--Haenszel method); otherwise, the random-effects model (DerSimonian--Laird method) was used.[@b10-ott-9-3683] Sensitivity analysis was also conducted to evaluate the effect of each study on the combined ORs and HRs by omitting each study in each turn. Besides, subgroup analyses according caner type, ethnicity, chemotherapy type, study type, evaluation criteria, mean age, and responder definition were also performed. Potential publication bias was checked by Begg's funnel plots and Egger's test.[@b11-ott-9-3683],[@b12-ott-9-3683] Stata 12.0 software (StataCorp, College Station, TX, USA) was used to perform all the analyses.

Results
=======

Study characteristics
---------------------

According to the searching strategy and the criteria of inclusion and exclusion, the literature was collected. As shown in [Figure 1](#f1-ott-9-3683){ref-type="fig"}, a total of 95 documents were initially retrieved, of which 25 were from PubMed, 33 were from EMBASE, and 37 were from Web of Science. After excluding 48 duplicated papers, 12 reviews or meeting abstracts, and 11 irrelevant papers, 24 articles were left for further evaluation. Then, a further 5 papers were excluded because they did not have sufficient data or had overlapping data. Finally, 19 eligible articles containing 3,217 cases were included in the meta-analysis.[@b9-ott-9-3683],[@b13-ott-9-3683]--[@b30-ott-9-3683] The characteristics of each included study are listed in the [Tables 1](#t1-ott-9-3683){ref-type="table"} and [S1](#SD1-ott-9-3683){ref-type="supplementary-material"}. These 19 articles were published from 2006 to 2014. Of these, 13 studies were performed in Caucasians and six were done in Asians. Eighteen articles reported *GSTM1* polymorphism--related data, while 13 articles reported *GSTT1* polymorphism.

Meta-analysis results
---------------------

### Associations of *GSTM1* and *GSTT1* polymorphisms with chemotherapy-related toxicities

Overall, no significance was found between overall toxicity, neurotoxicity, neutropenia, or gastrointestinal toxicity and the polymorphisms in *GSTM1* and *GSTT1* ([Table 1](#t1-ott-9-3683){ref-type="table"}). Then, subgroup analyses stratified by ethnicity, cancer type, evaluation criteria, study type, chemotherapy type, and mean age were performed to investigate the association of the toxicity with polymorphisms. Unfortunately, there was still no significant association identified between the toxicities and the polymorphisms, except for the neurotoxicity associated with *GSTM1* polymorphism in the Asian subgroup (OR =3.361, 95% CI =1.324--8.532, *P*=0.011); however, the number of included studies was less (n=2). Neutropenia associated with *GSTM1* polymorphism in palliative chemotherapy (OR =1.503, 95% CI =1.024--2.208, *P*=0.038) and elder patients with mean age \>60 years (OR =1.613, 95% CI =1.064--2.445, *P*=0.024; [Figure 2](#f2-ott-9-3683){ref-type="fig"} and [Table 2](#t2-ott-9-3683){ref-type="table"}).

### Associations of *GSTM1* and *GSTT1* polymorphisms with tumor response

No significant association was identified between polymorphisms in *GSTM1* and *GSTT1* and tumor response after chemotherapy in gastric and colorectal cancers in overall analysis; however, we observed that patients with *GSTT1* null genotype had a trend of lower response rate (OR =0.760, 95% CI =0.568--1.016, *P*=0.064; [Figure 2](#f2-ott-9-3683){ref-type="fig"} and [Table 3](#t3-ott-9-3683){ref-type="table"}). We also performed subgroup analysis according to ethnicity, cancer type, evaluation criteria, chemotherapy type, mean age, and responder definition, and the results revealed that *GSTT1* null genotype was associated with a lower tumor response in patients with gastric cancer (OR =0.674, 95% CI =0.466--0.974, *P*=0.036) and in responders, as defined by complete and partial response (CR + PR; OR =0.730, 95% CI =0.535--0.994, *P*=0.046; [Figure 2](#f2-ott-9-3683){ref-type="fig"} and [Table 3](#t3-ott-9-3683){ref-type="table"}).

### Associations of *GSTM1* and *GSTT1* polymorphisms with PFS and OS

There was no significant association between polymorphisms of *GSTM1* and *GSTT1* with PFS. For OS, data of six studies were available to analyze its association with *GSTM1*and *GSTT1* polymorphisms. After pooling analysis and subgroup analysis stratified by ethnicity, cancer type, and mean age, we found that *GSTM1* null type associated with a shorter OS in overall analysis (HR =1.213, 95% CI =1.060--1.388, *P*=0.005) and with subgroups of Caucasian (HR =1.222, 95% CI =1.000--1.493, *P*=0.050), Asian (HR =1.205, 95% CI =1.004--1.446, *P*=0.045), colorectal cancer (HR =1.226, 95% CI =1.044--1.438, *P*=0.013), and patients with mean age \<60 years (HR =1.206, 95% CI =1.013--1.435, *P*=0.035). *GSTT1* polymorphism was associated only with OS in the Caucasian subgroup (HR =1.299, 95% CI =1.046--1.613, *P*=0.018) and patients with mean age \>60 years (HR =1.370, 95% CI =1.063--1.765, *P*=0.015; [Figure 2](#f2-ott-9-3683){ref-type="fig"} and [Table 4](#t4-ott-9-3683){ref-type="table"}).

### Sensitivity analysis and publication bias

Sensitivity analysis was performed to examine the influence of individual studies on the pooled ORs by deleting each study once, and similar results were identified for all analyses. Begg's funnel plot and Egger's test were carried out to assess the publication bias among the included studies for chemotherapy efficacy and polymorphisms in *GSTM1* and *GSTT1* in gastric and colorectal cancers. Symmetrical funnel plots were obtained ([Figure 3](#f3-ott-9-3683){ref-type="fig"}). The results showed no evidence of publication bias ([Tables 2](#t2-ott-9-3683){ref-type="table"}[](#t3-ott-9-3683){ref-type="table"}--[4](#t4-ott-9-3683){ref-type="table"}). Sensitivity and publication bias analyses were not performed when the number of included original studies was less than three.

Discussion
==========

In this meta-analysis study, we pooled 19 publications to explore the associations between *GSTM1* and *GSTT1* polymorphisms and chemotherapy efficacy in gastric and colorectal cancers.

Chemotherapy has been widely used in the treatment of gastrointestinal malignancies, especially for metastatic or advanced cancers. The most common chemotherapeutic regimens involve the combination of oxaliplatin and irinotecan with fluoropyrimidines. However, the toxicity profile, tumor response, and prognosis of chemotherapy are very heterogeneous, even in a homologous regimen. It is well known that the individual genetic background may be a major cause for the variability of clinical outcomes. In recent years, a series of studies have tried to investigate the predictive value of the polymorphisms in genes involved in detoxification, metabolism, DNA repair, excretion, or transport on chemotherapy of gastrointestinal cancers.[@b22-ott-9-3683],[@b23-ott-9-3683] For example, polymorphisms in thymidylate synthase have been suggested to determine the cancer cell's sensitivity toward fluoropyrimidines;[@b31-ott-9-3683],[@b32-ott-9-3683] polymorphism in the methylenetetra-hydrofolate reductase gene associates with tumor response to 5-FU monotherapy in patients with advanced colorectal cancer;[@b33-ott-9-3683] polymorphism in dihydropyrimidine dehydrogenase associates with toxicity from fluoropymidines treatment;[@b34-ott-9-3683]--[@b38-ott-9-3683] and the mutations within the nucleotide excision repair pathway and the detoxifying GST may be correlated to resistance to platinum compounds.[@b39-ott-9-3683]--[@b41-ott-9-3683] In this study, we investigated the associations of polymorphisms in *GSTM1* and *GSTT1* with the chemotherapy-related toxicities, tumor response, and prognosis in gastrointestinal cancers for the first time. Pooling analysis revealed no significant association between the polymorphisms and the chemotherapy-related toxicity, tumor response, and prognosis except that *GSTM1* null genotype associated with poor OS. Further subgroup analyses suggested that ethnicity, cancer type, chemotherapy type, patient age, and responder definition might have an important influence on the associations. Notably, GSTs are involved in detoxification via direct glutathione conjugation of xenobiot-ics, and it might be more reasonable that a null genotype, resulting in no enzyme activity, would lead to better tumor response and prognosis after chemotherapy. However, our results suggested that *GSTM1* null genotype associated with poor OS, and a trend was also observed between *GSTT1* null type and poor tumor response and prognosis. The underlying mechanisms might be that the null genotypes of *GSTM1* and *GSTT1* reduced the GST activity, then elevated the glutathi-one levels, and finally decreased DNA binding capability of platinum compounds.[@b42-ott-9-3683]--[@b45-ott-9-3683] Besides, *GSTM1* and *GSTT1* might be involved in other signaling pathways that were critical for the metabolism of the chemotherapeutic drugs, which affected the associations and should be explored in the future.

Although we pooled all the potential studies to investigate the association between the polymorphisms of *GSTM1* and *GSTT1* and chemotherapy efficacy in gastrointestinal cancers, the publication number and the sample size were still limited. Another limitation of the meta-analysis was the potential instability of the conclusions resulting from the diversity among the original individual studies. In the present meta-analysis, we investigated the effects of the diversity on the result stability and reliability by performing subgroup analysis according to ethnicity, cancer type, toxicity/response criteria, chemotherapy type, study type, age, and responder definition. Additional factors should be taken into consideration as well. As listed in [Table S1](#SD1-ott-9-3683){ref-type="supplementary-material"}, we also extracted the following information, sex radio, ECOG scores, Karnofsky scale, metastatic sites number, disease stage, grade, pre-/postsurgery data, and prechemotherapy/-radiotherapy details, from original studies. The sex radio (male/female) ranged from 1.13 to 3.00. The ECOG scores, Karnofsky scale, metastatic sites, disease stage, and tumor grade were reported in ten, five, seven, seven, and three studies, respectively. The ECOG scores ranged from 0 to 2. Four hundred and thirty-three patients had a cancer at single metastatic site and 554 patients had multiple sites of metastasis, respectively. Two hundred and twenty-three patients were in Stage I--II, 589 patients were in Stage III, 590 patients were in Stage IV, 274 patients were in Grade I--II, and 202 patients in Grade II--IV, respectively. There were seven, nine, and one studies reporting previous/postsurgery, prechemotherapy, and preradiotherapy data, respectively. However, these original data were not sufficient for quantitatively evaluating the impact of the diversity among the included studies on the association of the polymorphisms with chemotherapy effi-cacy. Thus, further well-designed studies with larger sample size and more detailed information should be conducted to confirm the results.

Conclusion
==========

From the results of the current meta-analysis, it can be observed that the polymorphisms in *GSTM1* and *GSTT1* were not associated with the chemotherapy-related toxicities, tumor response, and prognosis in gastrointestinal cancers, except for *GSTM1* polymorphism being associated with OS. Subgroup analyses suggested that *GSTM1* polymorphism might be associated with neurotoxicity in Asians, with neutropenia in palliative chemotherapy and elder patients, and with OS in Caucasians, Asians, and those with colorectal cancer. *GSTT1* might be associated with tumor response in gastric cancer and with OS in Caucasians and elder patients.

Supplementary material
======================

###### 

Additional information of included studies

  Reference                         ECOG score   Karnofsky scale   Metastatic sites   Tumor stage   Tumor grade   Pre-/postsurgery   Prechemotherapy   Preradiotherapy   Responder definition                                                                                   
  --------------------------------- ------------ ----------------- ------------------ ------------- ------------- ------------------ ----------------- ----------------- ---------------------- ----- ---- --- ---- ----- ----- ---- ----- ----- -- --------- -------- -------- --------------
  Goekkurt et al[@b21-ott-9-3683]                                                                   27                               25                                  7                      18    27                                            37/52     3/52              CR + PR
  Lecomte et al[@b17-ott-9-3683]    34           25                5                                                                                                                                                6     52                        6/64      13/64             
  Romero et al[@b19-ott-9-3683]                                                                     37            12                 2                                   8                      43                        51                                  24/51             
  Ruzzo et al[@b22-ott-9-3683]                                                                      116                              59                                  75                     55    45                        40   80    55                                   CR + PR
  Ruzzo et al[@b23-ott-9-3683]                                                                      122                              44                                  99                     45    22                        11   119   32                 74/167            
  Ott et al[@b24-ott-9-3683]                                                                                                                                                                                                    24         115      133/139                     CR
  Goekkurt et al[@b15-ott-9-3683]   32           94                8                                                                                                     33                     44    57                                                                        CR + PR
  Huang et al[@b25-ott-9-3683]                                                                                                                                                                             3   15   73    11                        102/102                     
  Seo et al[@b20-ott-9-3683]                                                                                                                                                                                                                                  81/149            CR + PR
  Boige et al[@b13-ott-9-3683]      154          151               51                                                                                                    185                    161                                                                             CR + PR
  Funke et al[@b26-ott-9-3683]                                                                                                                                                                             5   48   187   98                                                    
  McLeod et al[@b18-ott-9-3683]     496                            24                                                                                                                                                                                         78/520            
  Shim et al[@b27-ott-9-3683]                                                                       77                               123                                                                                                            102/200   34/200            CR + PR
  Zarate et al[@b28-ott-9-3683]     54                             6                                                                                                                                                                                          18/60             CR + PR + SD
  Cecchin et al[@b14-ott-9-3683]                                                                                                                                                                                                                    144/144   13/144   19/144   
  Cortejoso et al[@b9-ott-9-3683]   91           65                6                                                                                                                                       1   12   31    118                                                   
  Kumamoto et al[@b16-ott-9-3683]   39           21                3                                                                                                     26                     37                                                                              CR + PR
  Lai et al[@b29-ott-9-3683]                                                                                                                                                                                   74   267   150                       491/491                     
  Kap et al[@b30-ott-9-3683]                                                                                                                                                                                   65   25    110                                                   

**Abbreviations:** ECOG, Eastern Cooperative Oncology Group; CR, complete response; PR, partial response; SD, standard deviation.

This study was supported by the grant of Application Value of Type M Color Echocardiography Technology in Evaluation of Right Ventricular Diastolic Function of Umbilical Fetus (number 141302115).
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![Flowchart of study selection.](ott-9-3683Fig1){#f1-ott-9-3683}

![Forest plots for the associations of *GSTM1* and *GSTT1* polymorphisms with toxicity, tumor response, and OS.\
**Notes:** (**A**) Association of *GSTM1* polymorphism with neurotoxicity stratified by ethnicity. (**B**) Association of *GSTM1* polymorphism with neutropenia stratified by chemotherapy. (**C**) Association of GSTT1 polymorphism with tumor response stratified by cancer type. (**D**) Association of *GSTM1* polymorphism with OS stratified by cancer type. The heterogeneity was assessed by the chi-square based on Q statistic test. Bold values show subgroup information.\
**Abbreviations:** OR, odds ratio; OS, overall survival; CI, confidence interval; GC, gastric cancer; CRC, colorectal cancer; HR, hazard ratio.](ott-9-3683Fig2){#f2-ott-9-3683}

![Begg's funnel plot for publication bias analysis for associations of *GSTM1* polymorphism with neurotoxicity (**A**), tumor response (**B**), and OS (**C**).\
**Abbreviations:** OS, overall survival, se, standard error; OR, odds ratio; HR, hazard ratio.](ott-9-3683Fig3){#f3-ott-9-3683}

###### 

Characteristics of the included studies

  Reference                         Country                      Ethnicity   Cases (M/F)     Age               Cancer type                                   Genotyping method                           Chemotherapy regimen                        Chemotherapy type      Clinical parameters                                                   Criteria           Genes
  --------------------------------- ---------------------------- ----------- --------------- ----------------- --------------------------------------------- ------------------------------------------- ------------------------------------------- ---------------------- --------------------------------------------------------------------- ------------------ ---------------------
  Goekkurt et al[@b21-ott-9-3683]   Germany                      Caucasian   52 (34/18)      56 (27--83)       AGC                                           PCR-RFLP                                    6-FU/cisplatin/FA                           Palliative             Response                                                              RECIST             *GSTM1* and *GSTT1*
  Lecomte et al[@b17-ott-9-3683]    France                       Caucasian   64 (35/32)      64 (24--87)       Gastrointestinal (colon and gastric cancer)   PCR                                         FOLFOX4/FOLFOX7/FOLFOX9/GEMOX/TOMOX         Palliative             Neurotoxicity                                                         OSS                *GSTM1* and *GSTT1*
  Romero et al[@b19-ott-9-3683]     Spain                        Caucasian   51 (38/13)      63 (41--77)       IV CRC                                        PCR-RFLP                                    5-Fu/CPT-11/Lv                              Palliative             Gastrointestinal and hematological toxicity                           NCI-CTC            *GSTM1* and *GSTT1*
  Ruzzo et al[@b22-ott-9-3683]      Japan                        Asian       175 (99/76)     61 (38--79)       AGC                                           PCR-RFLP                                    Fluorouracil/cisplatin                      Palliative             Response                                                              RECIST             *GSTM1* and *GSTT1*
  Ruzzo et al[@b23-ott-9-3683]      Italy                                    167 (87/79)     66                mCRC                                          PCR-RFLP                                    FOLFOX-4                                    Palliative             PFS                                                                                      *GSTM1* and *GSTT1*
  Ott et al[@b24-ott-9-3683]        Germany                      Caucasian   139 (101/38)    57±10             GC                                            Multiplex PCR                               Cisplatin                                   Neoadjuvant            OS, response                                                                             *GSTM1* and *GSTT1*
  Goekkurt et al[@b15-ott-9-3683]   Germany                      Caucasian   134 (92/42)     64 (27--86)       AGC                                           PCR                                         FU and platinum                             Palliative             Neurotoxicity, neutropenia, and anemia, response                      OSS and NCI-CTC    *GSTM1* and *GSTT1*
  Huang et al[@b25-ott-9-3683]      People's Republic of China   Asian       102 (73/29)     58 (34--74)       GC                                            PCR-LDR                                     Oxa-based FOLFOX                            Adjuvant               OS                                                                                       *GSTM1*
  Seo et al[@b20-ott-9-3683]        Korea                        Asian       75 (44/31)      56 (29--84)       AGC                                           PCR-RFLP                                    mFOLFOX                                     Palliative             Neurotoxicity, neutropenia, and response                              NCI-CTC            *GSTM1* and *GSTT1*
  Boige et al[@b13-ott-9-3683]      France                       Caucasian   346 (214/132)   67--68 (34--83)   mCRC                                          PCR                                         LV5FU2/FOLFOX/FOLFIRI                       Palliative             Overall toxicity, neurotoxicity, neutropenia, OS, PFS, and response   WHO and NCI-CTC    *GSTM1* and *GSTT1*
  Funke et al[@b26-ott-9-3683]      Germany                      Caucasian   338 (201/137)   64.8              CRC                                           Fluorescence-based melting curve/PCR        Chemotherapy                                Adjuvant/palliative    OS                                                                    RECIST             *GSTM1*
  McLeod et al[@b18-ott-9-3683]     Canada                       Caucasian   520 (306/214)   61 (26--85)       aCRC                                          Pyrosequencing                              IFL/FOLFOX/IROX                             Palliative             Neutropenia                                                           NCI-CTC            *GSTM1*
  Shim et al[@b27-ott-9-3683]       Korea                        Asian       200 (150/50)    58 (19--76)       GC                                            TaqMan/HRM                                  Taxane + cisplatin as first line            Neoadjuvant/adjuvant   OS, PFS, and response                                                 RECIST             *GSTM1* and *GSTT1*
  Zarate et al[@b28-ott-9-3683]     Spain                        Caucasian   60 (45/15)      58 (37--75)       mCRC                                          PCR-RFLP                                    Oxaliplatin, irinotecan, and capecitabine   Palliative             Response                                                              RECIST             *GSTM1* and *GSTT1*
  Cecchin et al[@b14-ott-9-3683]    Italy                        Caucasian   144 (82/62)     59 (25--82)       II--III CRC                                   Pyrosequencing/TaqMan                       FOLFOX4                                     Adjuvant               Neutropenia                                                           NCI-CTC            *GSTM1*
  Cortejoso et al[@b9-ott-9-3683]   Spain                        Caucasian   162 (95/67)     64 (38--85)       CRC                                           PCR/TaqMan/Snapshot                         Irinotecan/oxaliplatin-based treatment      Palliative             Overall toxicity                                                      CTCAE              *GSTT1*
  Kumamoto et al[@b16-ott-9-3683]   Japan                        Asian       63 (41/22)      65 (32--86)       CRC                                           PCR-RFLP                                    mFOLFOX8                                    Palliative             Neurotoxicity and response                                            CTCAE and RECIST   *GSTM1* and *GSTT1*
  Lai et al[@b29-ott-9-3683]        People's Republic of China   Asian       491 (260/231)   58.5±12.5         CRC                                           PCR-RFLP                                    5-FU based                                  Adjuvant               OS                                                                                       *GSTM1*
  Kap et al[@b30-ott-9-3683]        Germany                      Caucasian   431 (268/163)   66                CRC                                           Fluorescence-based melting curve analysis   5-FU/Cap/Oxa                                Adjuvant/palliative    OS                                                                                       *GSTM1*

**Abbreviations:** PFS, progression-free survival; OS, overall survival; AGC, advanced gastric cancer; CRC, colorectal cancer; GC, gastric cancer; mCRC, metastatic colorectal cancer; RECIST, response evaluation criteria in solid tumors; WHO, Word Health Organization; CTCAE, common terminology criteria for adverse events; PCR, polymerase chain reaction; PCR-LDR, polymerase chain reaction-ligase detection reaction; PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism; aCRC, advanced colorectal cancer; NCI-CTC, National Cancer Institute Common Toxicity Criteria; OSS, Oxaliplatin specified scale.

###### 

Associations of GSTM1 and GSTT1 polymorphisms with toxicities

  Toxicity                    Polymorphism     Subgroup analysis   N   OR (95% CI)                        *P*~OR~     M   *I*^2^ (%)   *P*~Heter~   *P*~Begg~   *P*~Egger~
  --------------------------- ---------------- ------------------- --- ---------------------------------- ----------- --- ------------ ------------ ----------- ------------
  Overall toxicity            GSTM1 (− vs +)   Overall             2   1.109 (0.634--1.940)               0.716       F   0.0          0.534                    
                              GSTT1 (− vs +)   NCI-CTC             2   1.432 (0.718--2.853)               0.308       F   1.8          0.313                    
                                               Overall             3   2.101 (0.458--9.646)               0.340       F   51.9         0.125        1.000       0.900
  Neurotoxicity               GSTM1 (− vs +)   Caucasian           4   0.891 (0.592--1.342)               0.582       F   0.0          0.699                    
                                               Asian               2   **3.361 (1.324--8.532)**           **0.011**   F   0.0          0.885                    
                                               GC                  2   1.442 (0.579--3.586)               0.432       F   36.9         0.208                    
                                               CRC                 3   1.298 (0.621--2.714)               0.485       R   61.1         0.076                    
                                               OSS                 2   0.701 (0.306--1.608)               0.402       F   0.0          0.632                    
                                               NCI-CTC             3   1.080 (0.692--1.685)               0.734       F   24.3         0.267                    
                                               Retrospective       2   1.436 (0.240--8.581)               0.691       R   79.4         0.028                    
                                               Prospective         4   1.051 (0.693--1.593)               0.816       F   0.0          0.433                    
                                               Age (\>60)          5   1.051 (0.718--1.538)               0.798       F   38.7         0.163                    
                                               Overall             6   1.129 (0.782--1.630)               0.516       F   38.8         0.147        0.707       0.480
                              GSTT1 (− vs +)   Caucasian           4   1.252 (0.757--2.069)               0.381       F   0.0          0.708                    
                                               Asian               2   1.105 (0.549--2.225)               0.780       F   0.0          0.706                    
                                               GC                  2   1.160 (0.523--2.575)               0.715       F   0.0          0.779                    
                                               CRC                 3   1.197 (0.713--2.010)               0.496       F   0.0          0.469                    
                                               OSS                 2   1.118 (0.406--3.077)               0.829       F   0.0          0.793                    
                                               NCI-CTC             3   1.281 (0.783--2.094)               0.324       F   0.0          0.529                    
                                               Retrospective       2   1.055 (0.455--2.445)               0.900       F   0.0          0.742                    
                                               Prospective         4   1.248 (0.782--1.992)               0.353       F   0.0          0.708                    
                                               Age (\>60)          5   1.190 (0.755--1.876)               0.454       F   0.0          0.810                    
                                               Overall             6   1.200 (0.798--1.804)               0.382       F   0.0          0.901        0.707       0.480
  Neutropenia                 GSTM1 (--vs +)   Caucasian           5   1.235 (0.880--1.734)               0.222       F   42.2         0.140                    
                                               GC                  2   1.352 (0.667--2.740)               0.408       F   0.0          0.408                    
                                               CRC                 4   1.130 (0.642--1.989)               0.673       R   52.1         0.100                    
                                               Palliative          5   **1.503** (**1.024**--**2.208**)   **0.038**   F   0.0          0.563                    
                                               Age (\<60)          2   0.792 (0.478--1.311)               0.364       F   0.0          0.526                    
                                               Age (\>60)          4   **1.613** (**1.064**--**2.445**)   **0.024**   F   0.0          0.590                    
                                               Overall             6   1.209 (0.877--1.667)               0.247       F   29.2         0.216        0.452       0.801
                              GSTT1 (− vs +)   Overall             2   1.167 (0.544--2.500)               0.692       F   0.0          0.505                    
  Gastrointestinal toxicity   GSTM1 (− vs +)   Overall             2   2.378 (0.868--6.511)               0.092       F   0.0          0.322                    
                              GSTT1 (− vs +)   Overall             2   1.192 (0.512--2.777)               0.684       F   0.0          0.771                    

**Notes:** The heterogeneity was assessed by the chi-square based on Q statistic test. Potential publication bias was checked by Begg's funnel plots and Egger's test. Bold values represent a significant association or presence of the trend.

**Abbreviations:** CI, confidence interval; GC, gastric cancer; CRC, colorectal cancer; NCI-CTC, NCI common toxicity criteria; OSS, Oxaliplatin specified scale; M, model; F, fixed model; R, random model.

###### 

Associations of GSTM1 and GSTT1 polymorphisms with tumor response

  Polymorphism    Subgroup analysis      N    OR      95% CI                 *P*~OR~     M   *I*^2^ (%)   *P*~Heter~   *P*~Begg~   *P*~Egger~
  --------------- ---------------------- ---- ------- ---------------------- ----------- --- ------------ ------------ ----------- ------------
  GSTM1 − vs +    Caucasian              7    1.123   0.842--1.498           0.429       F   0.0          0.451                    
                  Asian                  3    1.067   0.669--1.700           0.786       F   0.0          0.966                    
                  GC                     6    1.162   0.853--1.585           0.341       F   0.0          0.734                    
                  CRC                    5    1.021   0.684--1.524           0.920       F   0.0          0.411                    
                  RECIST                 6    1.141   0.811--1.604           0.448       F   0.0          0.590                    
                  WHO                    2    1.126   0.706--1.795           0.618       F   0.0          0.391                    
                  Others                 2    1.005   0.586--1.721           0.987       F   19.1         0.266                    
                  Palliative             8    1.094   0.823--1.453           0.536       F   0.0          0.613                    
                  Neoadjuvant/adjuvant   2    1.148   0.707--1.863           0.578       F   0.0          0.499                    
                  \<60                   5    1.039   0.669--1.545           0.851       F   0.0          0.603                    
                  \>60                   5    1.152   0.844--1.572           0.374       F   0.0          0.558                    
                  Responder (CR + PR)    8    1.129   0.869--1.467           0.366       F   0.0          0.865                    
                  Overall                10   1.107   0.867--1.415           0.415       F   0.0          0.753        0.474       0.448
  GSTT1 -- vs +   Caucasian              7    0.689   0.470--1.009           **0.056**   F   0.0          0.635                    
                  Asian                  3    0.873   0.557--1.368           0.553       F   0.0          0.865                    
                  GC                     6    0.674   **0.466**--**0.974**   **0.036**   F   0.0          0.664                    
                  CRC                    4    0.931   0.568--1.016           0.064       F   0.0          0.808                    
                  RECIST                 6    0.813   0.558--1.183           0.279       F   0.0          0.651                    
                  WHO                    2    0.836   0.465--1.505           0.551       F   0.0          0.962                    
                  Others                 2    0.513   0.240--1.095           0.085       F   0.0          0.399                    
                  Palliative             8    0.705   0.494--1.006           **0.054**   F   0.0          0.716                    
                  Neoadjuvant/adjuvant   2    0.884   0.534--1.463           0.631       F   0.0          0.695                    
                  \<60                   5    0.842   0.558--1.270           0.412       F   0.0          0.594                    
                  \>60                   5    0.688   0.456--1.037           0.074       F   0.0          0.724                    
                  Responder (CR + PR)    8    0.730   **0.535**--**0.994**   **0.046**   F   0.0          0.809                    
                  Overall                10   0.760   0.568--1.016           **0.064**   F   0.0          0.817        0.592       0.383

**Notes:** The heterogeneity was assessed by the chi-square based on Q statistic test. Potential publication bias was checked by Begg's funnel plots and Egger's test. Bold values represent significant association or presence of the trend.

**Abbreviations:** RECIST, response evaluation criteria in solid tumors; WHO, response evaluation according to Word Health Organization criteria; OR, odds ratio; CI, confidence interval; GC, gastric cancer; CRC, colorectal cancer; CR, complete response; PR, partial response; Others: did not report the response evaluation criteria; M, model; F, fixed model; R, random model.

###### 

Associations of GSTM1 and GSTT1 polymorphisms with PFS and OS

  PFS/OS   Comparison model   Subgroup analysis     N   HR          95% CI             *P*~HR~     M   *I* (%) [@b2-ott-9-3683]   *P*~Heter~   *P*~Begg~   *P*~Egger~
  -------- ------------------ --------------------- --- ----------- ------------------ ----------- --- -------------------------- ------------ ----------- ------------
  PFS      GSTM1 − vs +       Overall               2   0.980       0.738--1.301       0.889       F   0.0                        1.000                    
  PFS      GSTT1 − vs +       GC                    2   1.119       0.860--1.457       0.402       R   67.0                       0.082                    
                              Palliative            2   1.474       0.960--2.263       0.076       F   0.0                        0.400                    
                              \>60                  2   1.474       0.960--2.263       0.076       F   0.0                        0.400                    
                              Overall               3   1.123       0.877--1.438       0.359       F   34.0                       0.220        1.000       0.545
  OS       GSTM1 − vs +       Caucasian             3   **1.222**   **1.000--1.493**   **0.050**   F   0.0                        0.914                    
                              Asian                 3   **1.205**   **1.004--1.446**   **0.045**   F   0.0                        0.704                    
                              GC                    3   1.182       0.920--1.517       0.191       F   0.0                        0.722                    
                              CRC                   3   **1.226**   **1.044--1.438**   **0.013**   F   0.0                        0.913                    
                              \<60                  4   **1.206**   **1.013--1.435**   **0.035**   F   0                          0.876                    
                              \>60                  2   **1.225**   **0.990--1.515**   **0.062**   F   0                          0.660                    
                              Overall               6   **1.213**   **1.060--1.388**   **0.005**   F   0.0                        0.971        1.000       0.728
  OS       GSTT1 − vs +       Caucasian             4   **1.299**   **1.046--1.613**   **0.018**   F   0.0                        0.419                    
                              Asian                 2   0.953       0.643--1.410       0.808       R   75.0                       0.046                    
                              GC                    3   1.135       0.677--1.904       0.631       R   77.2                       0.012                    
                              CRC                   3   1.189       0.991--1.427       0.062       F   0.0                        0.916                    
                              Palliative/adjuvant   2   1.243       0.942--1.640       0.099       F   0.0                        0.957                    
                              \<60                  3   0.988       0.755--1.293       0.930       R   51.8                       0.126                    
                              \>60                  3   **1.370**   **1.063--1.765**   **0.015**   F   4.8                        0.350                    
                              Overall               6   1.144       0.920--1.421       0.226       R   51.3                       0.068        0.260       0.385

**Notes:** The heterogeneity was assessed by the chi-square based on Q statistic test. Potential publication bias was checked by Begg's funnel plots and Egger's test. Bold values represent significant association or presence of the trend.

**Abbreviations:** PFS, progression-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; GC, gastric cancer; CRC, colorectal cancer; M, model; F, fixed model; R, random model.
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